Korea’s No. 1 Corona 19 treatment, Celltrion,’Rekironaju’ supplied to medical institutions in the middle of this month-Gyeongbuk Ilbo

Korea’s No. 1 Corona 19 treatment, Celltrion,’Rekironaju’ supplied to medical institutions in the middle of this month-Gyeongbuk Ilbo

by

The government provides temporary direct supply until the establishment of a supply system between hospitals and manufacturers

The Ministry of Food and Drug Safety has licensed Celltrion’s new coronavirus infection (Corona 19) antibody treatment’Rekyronaju’ (ingredient name Regdanvimab CT-P59). The subject of administration is a mild to moderate adult patient with high risk of COVID-19. On the morning of the 5th, the Ministry of Food and Drug Safety granted approval of the product under the condition of submitting the results of phase 3 clinical trials for Rekkirona at a final inspection committee meeting attended by three external experts, including Chairman of the Central Pharmacy Review Committee, Yoo-hwan, and five members inside the Ministry of Food and Drug Safety, including Kim Kang-rip, head of the Food and Drug Administration. I decided to do it. The photo was released on December 22nd last year,’Rekkironaju’. Association material photo

The new coronavirus infection (Corona 19) antibody treatment drug developed in Korea will be supplied to medical institutions from mid-month.

The Central Defense Response Headquarters (Bang Dae-bon) announced on the 6th that the government will directly purchase Rekkironaju (ingredient name Legdanvimab CT-P59) for a limited time and supply it to medical institutions from mid-February.

The Ministry of Food and Drug Safety (Ministry of Food and Drug Safety) officially licensed Rekirona, developed by Celltrion the day before, as an antibody treatment for Corona 19.

Dae-bon Bang explained that it takes time to prepare the product, and the government directly supplies the treatment for a temporary period, and if a supply system is established between medical institutions and pharmaceutical companies, the inconvenience of use will be minimized.

Rekironaju is administered only to subjects approved by the Ministry of Food and Drug Safety.

The Ministry of Food and Drug Safety designates patients over 60 years of age with approval of Rekirona, mild patients with one or more chronic diseases of cardiovascular disease, chronic respiratory system disease, diabetes, and hypertension (underlying disease), and patients with pneumonia requiring oxygen therapy did.

In each medical institution, these patients can use Rekirona within 7 days of the onset of symptoms.

Copyright © Gyeongbuk Ilbo-Goodday Good News Unauthorized reproduction and redistribution prohibited

View other articles of the Alliance



Source